InvestSMART

Healius Limited (ASX:HLS)

ALERT: Price-sensitive ASX Announcement for HLS
Current share price for HLS : $0.430 -0.015 (-3.37%)+
Announcement
Release
19 Aug 2026 9:45AM
Price at Release
$0.445
Full Release
download
Summary
Healius Limited released its FY26 financial results showing significant operational improvements and disciplined cost management, leading to stronger underlying earnings despite sector volume and labour cost pressures. The company's underlying revenue increased by 2.1%, supported by fee growth in Pathology and Agilex Biolabs. Pathology revenues grew by 1.8%, with strong growth in Genomic Diagnostics and other key segments. Cost management efforts included a 0.8% containment in cost growth and a 5% reduction in full-time equivalent headcount. Healius also made notable technological investments, including AI and digital platforms, to enhance productivity. Despite a non-cash impairment charge of $332 million against goodwill, the company maintained confidence in leveraging carried forward tax losses. The sale process of Agilex Biolabs is ongoing, with strong interest from potential acquirers. Healius remains focused on restoring sustainable margin and cash flow performance, with plans to achieve mid to high single-digit EBIT margins by December 2028.
Key Points
  • Underlying EBITDA increased by 8.1% to $258.6 million.
  • Surpassed EBIT expectations with a 76.6% increase to $30.2 million.
  • Group revenue grew by 2.1% to $1.37 billion.
  • Pathology revenue rose by 1.8% to $1.33 billion.
  • Agilex Biolabs' revenue increased by 14.1% to $43.6 million.
  • Net debt ended at $32.8 million.
  • Non-cash impairment charge of $332 million against goodwill.
  • Implemented cost-saving initiatives and labor optimization programs.
  • Continued investment in AI and digital platforms for productivity.
  • Exploring sale of Agilex Biolabs with ongoing interest.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.